157 related articles for article (PubMed ID: 9355968)
1. Expression of hyaluronan in benign and malignant breast lesions.
Auvinen PK; Parkkinen JJ; Johansson RT; Agren UM; Tammi RH; Eskelinen MJ; Kosma VM
Int J Cancer; 1997 Oct; 74(5):477-81. PubMed ID: 9355968
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
5. Cellular expression of growth hormone and prolactin receptors in human breast disorders.
Mertani HC; Garcia-Caballero T; Lambert A; Gérard F; Palayer C; Boutin JM; Vonderhaar BK; Waters MJ; Lobie PE; Morel G
Int J Cancer; 1998 Apr; 79(2):202-11. PubMed ID: 9583737
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan.
Auvinen P; Tammi R; Tammi M; Johansson R; Kosma VM
Histopathology; 2005 Oct; 47(4):420-8. PubMed ID: 16178897
[TBL] [Abstract][Full Text] [Related]
7. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
8. [P21 expression of ras oncogene product in benign and malignant female mammary lesions].
Zhang JZ; Fan SC; Liu HF
Zhonghua Bing Li Xue Za Zhi; 1994 Oct; 23(5):302-3. PubMed ID: 7874767
[TBL] [Abstract][Full Text] [Related]
9. Altered mucin expression is a field change that accompanies mucinous (colloid) breast carcinoma histogenesis.
O'Connell JT; Shao ZM; Drori E; Basbaum CB; Barsky SH
Hum Pathol; 1998 Dec; 29(12):1517-23. PubMed ID: 9865841
[TBL] [Abstract][Full Text] [Related]
10. Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions.
Kuroda N; Jin YL; Hamauzu T; Toi M; Miyazaki E; Hiroi M; Moriki T; Enzan H
Histol Histopathol; 2005 Jul; 20(3):707-12. PubMed ID: 15944918
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical demonstration of histone H1(0) in human breast carcinoma.
Kostova NN; Srebreva LN; Milev AD; Bogdanova OG; Rundquist I; Lindner HH; Markov DV
Histochem Cell Biol; 2005 Nov; 124(5):435-43. PubMed ID: 16158288
[TBL] [Abstract][Full Text] [Related]
12. Lectin binding patterns in benign and malignant lesions of the breast.
Karuna V; Shanthi P; Madhavan M
Indian J Pathol Microbiol; 1992 Oct; 35(4):289-97. PubMed ID: 1344218
[TBL] [Abstract][Full Text] [Related]
13. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
Reis-Filho JS; Steele D; Di Palma S; Jones RL; Savage K; James M; Milanezi F; Schmitt FC; Ashworth A
Mod Pathol; 2006 Feb; 19(2):307-19. PubMed ID: 16424897
[TBL] [Abstract][Full Text] [Related]
14. p53 protein expression in benign and malignant breast lesions.
Ioakim-Liossi A; Markopoulos C; Karakitsos P; Safioleas M; Gogas J; Vaiopoulos G
Acta Cytol; 1998; 42(4):918-22. PubMed ID: 9684577
[TBL] [Abstract][Full Text] [Related]
15. Nucleolar organizer regions in human breast cancer.
Roller E; Fritz P; Wicherek C; Klumpp B; Lauinger J; Mischlinski A; Wanner B; Schumacher K
Zentralbl Pathol; 1993 Aug; 139(3):195-9. PubMed ID: 8218120
[TBL] [Abstract][Full Text] [Related]
16. Armc8 expression was elevated during atypia-to-carcinoma progression and associated with cancer development of breast carcinoma.
Fan C; Zhao Y; Mao X; Miao Y; Lin X; Jiang G; Zhang X; Han Q; Luan L; Wang E
Tumour Biol; 2014 Nov; 35(11):11337-43. PubMed ID: 25119601
[TBL] [Abstract][Full Text] [Related]
17. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
Ma YH; Wang K; Li L; Lu ZH; Chen J
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
[TBL] [Abstract][Full Text] [Related]
18. Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast.
Prasad ML; Hyjek E; Giri DD; Ying L; O'Leary JJ; Hoda SA
Am J Surg Pathol; 1999 Feb; 23(2):176-81. PubMed ID: 9989844
[TBL] [Abstract][Full Text] [Related]
19. Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast.
Concha A; Ruiz-Cabello F; Cabrera T; Nogales F; Collado A; Garrido F
Eur J Immunogenet; 1995 Aug; 22(4):299-310. PubMed ID: 7495782
[TBL] [Abstract][Full Text] [Related]
20. [Cystic hypersecretory carcinoma with microinvasive carcinoma and cystic hypersecretory hyperplasia of breast: report of a case].
Chen DB; Kan X
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):54-5. PubMed ID: 20388402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
